in gene therapy
Jaguar Gene Therapy’s mission is to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. We built the company on a foundation of four elements that will allow us to deliver for patients – our team of experts, our initial pipeline, our confidence in the well-characterized AAV platform and our partnership with Deerfield Management.
From bench to bedside as safely and quickly as possible
Our goal is to improve the quality of life of patients with severe genetic diseases through the development of gene therapy treatments that confront diseases head-on, targeting the nonworking or missing gene by introducing healthy copies of the gene back into the body to restore function. Our team is working tirelessly to identify critical clinical needs and address them by expediting the development of gene therapies from bench to bedside as safely and quickly as possible.
The need is urgent
All over the world there are patients, families and physicians in critical need of a disease-modifying treatment for severe genetic diseases. Too often they are faced with the horrible truth that nothing can be done; there are no options.
Jaguar Gene Therapy is uniquely positioned to accelerate breakthroughs in gene therapy
Our team is led by the former leadership team of gene therapy pioneer, AveXis, and resourced by Deerfield Management, a healthcare-specific investment firm. We built the company on a foundation of four key elements that will allow us to deliver for patients – our team of experts, our initial pipeline, our confidence in the well-characterized AAV platform and our partnership with Deerfield Management.
- Experienced management team with world-class clinical and AAV GMP manufacturing expertise
- Current pipeline that targets diseases with significant unmet need
- Leveraging the proven and well-characterized AAV platform
- Access to Deerfield’s financial resources and existing network of 18 key academic institutions
JAG101 is designed to address the root cause of Type 1 galactosemia by delivering the functional GALT gene to reduce multiple toxic metabolites JAG201 is […]
Facility leverages company’s internal CMC expertise and expands its strategic capabilities from process development through commercial GMP production Company anticipates internal control of all CMC […]